C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling.
about
Natriuretic Peptides and Cardiometabolic HealthAtrial natriuretic peptide in cardiovascular biology and disease (NPPA)Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. [Corrected]C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP.Endothelial C-type natriuretic peptide maintains vascular homeostasis.Corin in natriuretic peptide processing and hypertensionDistinct roles of N-glycosylation at different sites of corin in cell membrane targeting and ectodomain shedding.A corin variant identified in hypertensive patients that alters cytoplasmic tail and reduces cell surface expression and activityThe C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells.Atrial natriuretic Peptide single nucleotide polymorphisms in patients with nonfamilial structural atrial fibrillation.Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study.Natriuretic peptides in cardiovascular diseases: current use and perspectivesAtrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases.Molecular Physiology of Membrane Guanylyl Cyclase Receptors.Natriuretic peptide activation of extracellular regulated kinase 1/2 (ERK1/2) pathway by particulate guanylyl cyclases in GH3 somatolactotropes.Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolismC2238/αANP modulates apolipoprotein E through Egr-1/miR199a in vascular smooth muscle cells in vitro.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases.T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients.
P2860
Q26827702-1A7EDFB0-6B83-45BA-9DE7-105091DD305CQ28082833-BF4BC26C-ABD4-466D-B8EF-A0EE4A21E56AQ33793053-19627F64-7469-40B2-854A-2550E8491309Q33812913-ADCD56A1-7176-43B6-A1F8-4FCA772D0226Q34117544-DD958D9E-0D28-4CC2-9836-864D9361EE08Q34396853-E69BD6E1-BBA0-4297-B639-53C0C2994428Q34450973-A11FBFE1-0688-405C-BCE0-7F8454CE30F8Q34452715-E87073C8-956F-427A-8601-BF3808248686Q35425744-CA33ABA3-A0F6-441C-ACBE-D63AEF6926C2Q37195866-BD8BC80E-B8B9-4997-B6D0-80094BBDDEBAQ37638257-85E8933B-C34E-44CD-ABF1-586DE7C056B3Q38162429-83FD77BE-0799-4030-9410-0F6FF20EEB7CQ38194620-040FF288-0509-4279-AC29-5831BA866F71Q38794203-EC7C5795-6F20-4FE6-8F3D-DECAF0168C0DQ41581124-AF68BDB4-8BF9-49B4-A172-011320CF4BE7Q42010491-81D4C4F7-405C-479D-B0B2-D1D003A53FBEQ43076955-E3E8CD1C-CD2D-4086-ADA1-CCE283633CECQ47855200-CA823B9B-FE69-4AE7-9069-577201353737Q50034119-590A557D-DF0A-4DB3-B5BD-E8042EF116B4Q50055077-4EAE9086-E75C-41C8-9E75-3A870D8CC134
P2860
C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
C2238 atrial natriuretic pepti ...... peptide receptor C signaling.
@en
type
label
C2238 atrial natriuretic pepti ...... peptide receptor C signaling.
@en
prefLabel
C2238 atrial natriuretic pepti ...... peptide receptor C signaling.
@en
P2093
P50
P1433
P1476
C2238 atrial natriuretic pepti ...... c peptide receptor C signaling
@en
P2093
Amie Moyes
Ivano Eberini
Lorenzo Castello
Sara Di Castro
P304
P356
10.1161/CIRCRESAHA.113.301325
P50
P577
2013-03-25T00:00:00Z